Nov 19, 2025, The 24th “Startup Award” ceremony, hosted by the Ministry of Economic Affairs (MOEA), was grandly held yesterday at the NTUH International Convention Center. Spirit Scientific BioTech (7790), which focuses on precision regenerative medicine, was honored with the “Startup Award” in the Technology Industry category, demonstrating recognition for its technical innovation and outstanding operating performance.Spirit Scientific BioTech stated that it holds the core technology of Biological Material Lyophilization Technology (BMLT ®) and has developed an innovative service model: the Biofoundry™ Diamond-Grade Lyophilization Preparation Service. This model provides standardized and precise biological material preparation, along with a comprehensive, end-to-end service solution that includes a smart collection and inspection management system.
It has already been implemented in clinical applications, offering a new alternative for regenerative medicine.Founder and Chairman, Steven D Lin, MD, commented that Spirit Scientific BioTech’s innovative technology and operating model have been fully validated in the Taiwan market, demonstrating strong profitability, and the company is also actively expanding its presence on the international stage.For example, from November 1st to 3rd this year, Spirit Scientific BioTech showcased its BMLT Technology Platform at the “Jihiken Festival 2025” (自費研フェスティバル2025), a major Japanese exhibition for self-pay medical services.
The company received numerous inquiries from manufacturers seeking OEM/ODM services to address issues such as the inability to preserve, transport, or validate emerging biological materials. Spirit Scientific BioTech is poised to assist in translating their R&D achievements into practical medical applications.Spirit Scientific BioTech further announced that its revenue for the first three quarters of 2025 reached NT$212 million, marking a 33% year-over-year increase. Its Japanese subsidiary, which began trial operations in May, is simultaneously pursuing regulatory certification and confirming client needs. The subsidiary is anticipated to formally commence order acceptance in 2026 after client demand verification is complete, which is expected to become a new growth driver for the company.According to the MOEA website, the “Startup Award” by the Small and Medium Enterprise and Startup Administration of the MOEA aims to establish successful benchmarks and foster an innovative and entrepreneurial Spirit Scientific BioTech in Taiwan. The award selects new ventures with superior operating models and products, technologies, processes, or services that are independently researched, developed, and possess market innovation.
Source: https://news.gbimonthly.com/tw/article/show.php?num=81847
